GCC Liquid Biopsy Market Report by Product, Application, Circulating Biomarkers, End-User, Countries and Companies Analysis 2026-2034

GCC Liquid Biopsy Market Size and Forecast

The GCC Liquid Biopsy Market is projected to grow from US$ 11.61 Million in 2025 to US$ 36.58 Million by 2034, registering a CAGR of 13.6% during 2026–2034. The market is expected to witness strong expansion as healthcare systems across GCC countries increasingly adopt minimally invasive molecular diagnostic technologies for cancer detection, treatment selection, and disease monitoring. Rising cancer incidence and the growing emphasis on early diagnosis are creating greater demand for liquid biopsy solutions based on circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and other biomarkers.

What is Liquid Biopsy and its Uses & Popularity in GCC

Liquid biopsy is a minimally invasive diagnostic approach that analyzes biological markers released by tumors into body fluids, primarily blood. Unlike conventional tissue biopsy, which requires removal of a tissue sample, liquid biopsy can detect and monitor circulating tumor DNA (ctDNA), cell-free DNA (cfDNA), circulating tumor cells (CTCs), and other molecular biomarkers. Its applications include early cancer detection, tumor profiling, treatment selection, therapy monitoring, detection of treatment resistance, and recurrence monitoring. The technology is gaining importance across the GCC as healthcare systems increasingly emphasize precision oncology and advanced molecular diagnostics.

In 2020, the GCC recorded approximately 42,475 new cancer cases and 19,895 cancer deaths, with breast, colorectal, and thyroid cancers accounting for nearly 40% of new cases. By 2040, cancer cases could approach 103,000 if current incidence rates remain unchanged. Growing adoption of next-generation sequencing (NGS), genomic profiling, and minimally invasive testing is strengthening liquid biopsy utilization in Saudi Arabia, the UAE, Qatar, Kuwait, Bahrain, and Oman.

Saudi Arabia Statistics at a Glance, 2024

• Population: Saudi Arabia had a total population of 33,962,761, comprising 20,559,494 males and 13,403,271 females.
• New Cancer Cases: The country recorded 24,624 new cancer cases, including 14,055 among males and 10,569 among females.
• Age-Standardized Incidence Rate: The cancer incidence rate was 95.8 per 100,000 population for both sexes, compared with 93.9 for males and 103.7 for females.
• Cumulative Risk of Developing Cancer: The risk of developing cancer before age 75 was 10.5% for both sexes, with 10.4% for males and 11.1% for females.
• Leading Cancers by New Cases: Among males, the top three cancers were colorectal, non-Hodgkin lymphoma (NHL), and prostate cancer. Among females, the leading cancers were breast, thyroid, and colorectal cancer. For both sexes combined, breast, colorectal, and thyroid cancers ranked highest.
• Cancer Deaths: Saudi Arabia recorded 10,357 cancer deaths, including 6,593 male deaths and 3,764 female deaths.
• Age-Standardized Mortality Rate: The mortality rate was 44.7 per 100,000 population for both sexes, compared with 48.1 for males and 41.0 for females.
• Cumulative Risk of Cancer Death: The probability of dying from cancer before age 75 was 5.2% for both sexes, including 5.6% for males and 4.8% for females.
• Leading Causes of Cancer Death: Colorectal, breast, and lung cancers were the three leading cancers by deaths among both sexes. For males, colorectal, lung, and liver cancers ranked highest, while breast, colorectal, and brain/CNS cancers led among females.
• Five-Year Cancer Prevalence: Saudi Arabia had 76,672 people living with cancer who had been diagnosed within the previous five years, comprising 41,451 males and 35,221 females.
• Cancer-Control Context: Saudi Arabia became a participating state of the International Agency for Research on Cancer (IARC) in May 2024, strengthening its engagement in cancer research and prevention.

Growth Drivers of the GCC Liquid Biopsy Market

Rising Cancer Burden and Demand for Early Detection

The increasing cancer burden across GCC countries is creating a substantial need for faster, less invasive, and repeatable diagnostic technologies. In 2020, approximately 42,475 new cancer cases were recorded across the GCC, while nearly 19,895 deaths were attributed to cancer. Breast cancer represented 16% of new cases, colorectal cancer 13%, and thyroid cancer 9%, highlighting the need for effective molecular diagnostics across multiple tumor types. The regional cancer burden is expected to rise considerably, with projections indicating approximately 103,000 new cases by 2040, compared with around 42,500 in 2020. Qatar and the UAE are projected to experience particularly substantial increases, while Saudi Arabia could see its incidence burden more than double. Liquid biopsy provides a convenient blood-based approach that can support cancer screening, molecular characterization, treatment monitoring, and recurrence surveillance. Increasing awareness of early diagnosis and the need to improve cancer outcomes are therefore encouraging hospitals and diagnostic laboratories to incorporate liquid biopsy into oncology pathways. As cancer care becomes increasingly molecularly driven, demand for ctDNA, cfDNA, CTC, and NGS-based testing is expected to increase throughout the GCC.

Expansion of Precision Oncology and Genomic Testing

The growing adoption of precision oncology is another major driver of the GCC liquid biopsy market. Liquid biopsy enables clinicians to identify tumor-associated genetic alterations without repeatedly performing invasive tissue biopsies, supporting personalized treatment selection and monitoring. Across the broader Middle East market, therapy selection reflecting the importance of molecular profiling in targeted cancer treatment. NGS-enabled liquid biopsy assays are increasingly being used for cancers such as lung, breast, colorectal, and prostate cancer. Saudi Arabia is also strengthening its genomics and precision-oncology ecosystem, with growing demand for liquid biopsy and minimal-residual-disease testing. A notable example is King Faisal Specialist Hospital & Research Centre, which adopted liquid biopsy technology capable of analyzing approximately 50 cancer-related genes and more than 3,000 clinically relevant mutations from a 10 mL blood sample. Such developments demonstrate how genomic testing is moving beyond research applications toward clinical oncology. Continued investment in sequencing infrastructure, molecular laboratories, bioinformatics, and personalized medicine programs is expected to support liquid biopsy adoption across GCC healthcare systems.

Healthcare Modernization and Investment in Advanced Diagnostics

Healthcare modernization across the GCC is accelerating the deployment of advanced diagnostic technologies, including liquid biopsy. Governments and healthcare institutions are investing in specialized cancer centers, molecular laboratories, genomic medicine, and precision-health infrastructure to improve diagnosis and treatment outcomes. The GCC healthcare environment is supported by relatively high levels of healthcare infrastructure development and rapid adoption of advanced medical technologies. Hospitals and laboratories are supported by advanced diagnostic infrastructure, higher patient volumes, and growing use of precision-oncology technologies. Saudi Arabia, the UAE, Qatar, Kuwait, Bahrain, and Oman are increasingly developing specialized healthcare capabilities, creating opportunities for liquid biopsy providers, sequencing companies, diagnostic laboratories, and technology suppliers. The shift toward minimally invasive testing is particularly attractive because blood-based testing can facilitate repeated molecular assessments during a patient’s treatment journey. As GCC healthcare systems expand cancer-screening programs and integrate genomic information into clinical decision-making, demand for liquid biopsy platforms, reagents, sequencing services, and interpretation solutions is expected to strengthen. These investments are helping transform liquid biopsy from a specialized technology into an increasingly relevant component of advanced cancer care.

Challenges of the GCC Liquid Biopsy Market

High Testing Costs and Limited Reimbursement

High costs associated with liquid biopsy testing remain an important barrier to wider adoption across the GCC. Advanced liquid biopsy workflows may require specialized blood-collection procedures, circulating DNA or tumor-cell isolation, NGS platforms, bioinformatics infrastructure, and highly trained molecular-diagnostics personnel. These requirements can make testing more expensive than conventional diagnostic approaches, particularly when comprehensive genomic panels are used. Smaller hospitals and diagnostic laboratories may therefore face difficulties justifying investment in sequencing equipment and specialized laboratory infrastructure. Reimbursement policies can also influence adoption because liquid biopsy applications continue to evolve across screening, therapy selection, treatment monitoring, and minimal-residual-disease assessment. Where reimbursement coverage is limited or inconsistent, patients and healthcare providers may hesitate to use advanced tests routinely. The challenge is particularly relevant for applications such as early cancer screening, where large populations would need to be tested. Expanding insurance coverage, establishing clinical guidelines, demonstrating cost-effectiveness, and increasing local laboratory capacity will be important for reducing financial barriers. Greater standardization of testing pathways could also help GCC healthcare systems achieve economies of scale and make liquid biopsy more accessible.

Technical Complexity, Validation and Skilled-Labor Requirements

Technical complexity and the need for specialized expertise represent another challenge for the GCC liquid biopsy market. Liquid biopsy requires highly sensitive technologies capable of detecting small quantities of tumor-derived genetic material within circulating blood. Factors such as low ctDNA concentrations, biological variability, sample handling, sequencing errors, and differences in laboratory protocols can affect test performance. Consequently, laboratories need qualified molecular pathologists, genetic specialists, bioinformaticians, and technicians to process and interpret results accurately. The challenge becomes greater when comprehensive NGS panels generate large volumes of genomic information requiring clinical interpretation. GCC countries are rapidly expanding their precision-medicine infrastructure, but specialized capabilities and experienced personnel may remain concentrated in major healthcare centers. For example, hospitals and laboratories currently represent the largest end-user segment of the regional liquid biopsy market, reflecting the importance of advanced infrastructure for adoption. Establishing standardized protocols, quality-control systems, validation requirements, and professional training programs will therefore be essential. Greater regional collaboration between hospitals, diagnostic laboratories, genomic institutions, and technology providers can help address skills shortages and improve consistency in liquid biopsy testing.

Liquid Biopsy Launches Worldwide

• Labcorp Plasma Complete™ – 2025: Labcorp announced the clinical availability of Plasma Complete in February 2025. The ctDNA-based comprehensive genomic profiling test uses a blood sample to help guide personalized treatment decisions for patients with advanced solid tumors.
• NeoGenomics NEO PanTracer™ LBx – 2025: NeoGenomics launched PanTracer LBx in July 2025 as a blood-based comprehensive genomic profiling test. It analyzes more than 500 genes and supports therapy selection, clinical-trial matching, and longitudinal disease monitoring.
• Labcorp Plasma Detect™ – 2025: Labcorp expanded Plasma Detect into clinical use in April 2025 for assessing recurrence risk in stage III colon cancer. The tumor-informed MRD test uses whole-genome sequencing and can detect ctDNA at a reported LOD95 of 0.005%.
• Guardant360® Smart Liquid Biopsy Upgrade – 2024: Guardant Health launched a major upgrade to Guardant360 in July 2024. The enhanced test evaluates 739 genes, approximately 10 times the previous biomarker coverage, and provides results in 7–10 days.
• MSK-ACCESS® Powered with SOPHiA DDM™ – 2024: SOPHiA GENETICS and AstraZeneca expanded global deployment of MSK-ACCESS in 2024. The liquid biopsy solution was launched across an initial group of 14 healthcare institutions, with plans to reach 20 institutions worldwide.
• GeneCentric EXpressCT™ – 2024: GeneCentric Therapeutics launched EXpressCT, a liquid biopsy platform designed to assess RNA expression and epigenomic signals from samples including blood and urine, expanding liquid biopsy beyond conventional DNA-based analysis.
• Delfi FirstLook® Lung – 2023: Delfi Diagnostics launched FirstLook Lung in October 2023 as a blood-based test intended to identify individuals who could benefit most from lung cancer screening. The test uses DNA-fragmentation patterns in blood.
• Labcorp Plasma Focus™ – 2023: Labcorp launched Plasma Focus in May 2023 for patients with advanced or metastatic solid tumors. The liquid biopsy analyzes circulating cell-free DNA to help oncologists identify targeted treatment options.
• FoundationOne® Liquid CDx – 2024 Indication Expansion: Foundation Medicine’s FoundationOne Liquid CDx received an FDA approval in 2024 as a companion diagnostic for Itovebi (inavolisib) in patients with PIK3CA-mutated, HR-positive, HER2-negative advanced or metastatic breast cancer.
• Guardant Shield™ – 2024 U.S. Commercial Launch: Guardant Health’s Shield blood test became commercially available in the U.S. in August 2024 as an FDA-approved primary screening option for colorectal cancer, representing an important expansion of blood-based cancer testing into population screening.

GCC Kits & Reagents Market

The GCC kits and reagents segment represents a recurring component of the liquid biopsy value chain because every molecular testing workflow requires consumable materials. Demand is increasing for cell-free DNA extraction kits, ctDNA isolation reagents, CTC enrichment products, mutation-detection reagents, PCR assays, and NGS library-preparation materials. The GCC liquid biopsy market is explicitly segmented into kits and reagents, platforms and instruments, and services, reflecting the growing importance of consumables alongside capital equipment and laboratory services. Molecular laboratories across Saudi Arabia, the UAE, Qatar, Kuwait, Bahrain, and Oman require reliable consumables to process blood samples and generate genomic profiles. The expansion of NGS and precision-oncology programs is increasing the volume and complexity of testing, creating recurring demand for high-sensitivity reagents. In addition, GCC laboratories remain heavily dependent on imported finished DNA-extraction reagent kits, with demand concentrated in clinical diagnostics and research applications.

GCC Reproductive Health Market

Liquid biopsy technologies are also gaining relevance in GCC reproductive health, particularly through cell-free DNA applications such as non-invasive prenatal testing (NIPT). Unlike oncology-focused liquid biopsy, reproductive applications analyze fetal genetic material circulating in maternal blood to screen for chromosomal abnormalities. NIPT can reduce reliance on invasive diagnostic procedures while providing early genetic-risk information. The GCC’s expanding genomic-medicine infrastructure is creating favorable conditions for wider adoption of cfDNA-based reproductive testing. Saudi Arabia, the UAE, Qatar, Kuwait, Bahrain, and Oman are investing in genetic testing and precision-health capabilities, while major healthcare institutions are developing specialized molecular laboratories. KFSH&RC’s broader genomic-medicine ecosystem illustrates the region’s growing clinical use of advanced genetic testing; its precision-medicine work includes accredited laboratories and extensive genomic interpretation capabilities. Rising awareness of prenatal screening, greater availability of genetic counseling, and improvements in sequencing technologies are supporting demand for cfDNA testing. The reproductive-health application therefore provides liquid biopsy companies with an additional growth opportunity beyond oncology. As GCC healthcare systems increasingly integrate genetic screening into maternal and family-health services, demand for NIPT kits, sequencing services, bioinformatics, and confirmatory testing is expected to increase.

GCC Circulating Tumor DNA (ctDNA) Market

GCC circulating tumor DNA (ctDNA) market is becoming a central component of regional liquid biopsy development because ctDNA provides molecular information about tumors through a blood sample. Applications include identifying actionable mutations, assessing treatment response, monitoring minimal residual disease, detecting emerging resistance, and supporting recurrence surveillance. Advances in NGS and other molecular technologies are improving the sensitivity of ctDNA analysis and expanding its clinical usefulness.  Saudi Arabia and the UAE are particularly important markets. KFSH&RC demonstrated the clinical potential of blood-based testing by implementing a liquid biopsy technology capable of analyzing around 50 cancer-related genes and more than 3,000 mutations from a 10 mL blood sample. Meanwhile, the UAE’s 2025 M42-AstraZeneca-SOPHiA GENETICS initiative is integrating the MSK-ACCESS assay into testing infrastructure to provide non-invasive genomic profiling for multiple cancer types. These developments are strengthening clinical confidence in ctDNA testing. As precision oncology expands across GCC hospitals and diagnostic laboratories, ctDNA is expected to gain greater importance in personalized treatment selection, longitudinal monitoring, and molecular disease management.

United Arab Emirates Liquid Biopsy Market

United Arab Emirates (UAE) liquid biopsy market is emerging as an important segment of the country’s precision-oncology and advanced diagnostics ecosystem. The UAE is strengthening genomic medicine through investments in molecular laboratories, cancer diagnostics, and partnerships between healthcare institutions and global technology companies. A major milestone occurred in June 2025, when M42, AstraZeneca, and SOPHiA GENETICS announced a strategic collaboration to introduce MSK-ACCESS liquid biopsy testing into the UAE healthcare infrastructure. The program uses a simple blood draw for non-invasive genomic profiling and initially targets lung, ovarian, breast, colorectal, and pancreatic cancers. Validation studies were planned at Cleveland Clinic Abu Dhabi before broader implementation across selected hospitals. UAE’s broader precision-medicine ecosystem is also supported by M42’s multi-omics capabilities and collaborations aimed at improving personalized cancer prevention and treatment. In 2024, M42 and AstraZeneca announced a program covering hereditary breast-cancer gene sequencing across the UAE, Kuwait, Oman, Bahrain, and Qatar. Increasing cancer awareness, demand for minimally invasive testing, and the UAE’s focus on advanced healthcare technologies are expected to accelerate adoption of ctDNA, cfDNA, NGS-based testing, and molecular monitoring.

Bahrain Liquid Biopsy Market

Bahrain’s liquid biopsy market is developing alongside growing demand for early cancer detection, molecular diagnostics, and personalized oncology. According to the 2024 Bahrain National Cancer Registry, the country recorded 1,401 new cancer cases, including 1,230 among Bahraini nationals and 171 among non-Bahrainis. More than half of cases were diagnosed at localized stages, while approximately 12.7% were metastatic at initial diagnosis, highlighting the importance of improving cancer detection and disease monitoring. Liquid biopsy can complement conventional tissue-based diagnosis by providing blood-based information on ctDNA, circulating tumor cells, and other biomarkers. Its ability to support repeated testing is particularly relevant for monitoring treatment response and identifying molecular changes during therapy. Bahrain’s participation in regional genomics and precision-medicine initiatives is also strengthening its diagnostic capabilities. M42’s 2024 partnership with AstraZeneca included sequencing and personalized cancer-care initiatives covering Bahrain alongside other GCC markets. As molecular laboratories, oncology services, and genomic testing capabilities expand, demand for liquid biopsy kits, reagents, sequencing services, and biomarker-analysis platforms is expected to increase.

Saudi Arabia Liquid Biopsy Market

Saudi Arabia represents one of the leading markets for liquid biopsy adoption in the GCC, supported by advanced oncology infrastructure and growing investment in precision medicine. A major milestone occurred in October 2023, when King Faisal Specialist Hospital & Research Centre (KFSH&RC) adopted liquid biopsy technology capable of detecting approximately 50 cancer-associated genes and more than 3,000 genetic mutations from a 10 mL blood sample. The technology supports tumor-biomarker detection, treatment-response assessment, identification of emerging mutations, and recurrence monitoring. The development aligns with Saudi Arabia’s broader expansion of genomic medicine and advanced cancer diagnostics. Liquid biopsy offers particular value because samples can be collected repeatedly without requiring repeated invasive tissue procedures. This enables clinicians to track molecular changes throughout treatment and potentially identify actionable mutations earlier. Hospitals and laboratories already represent the largest end-user segment across the broader Middle East liquid biopsy market in 2024. Saudi Arabia’s sophisticated hospital network, investment in molecular diagnostics, and increasing emphasis on personalized cancer treatment are therefore expected to sustain strong demand for ctDNA, cfDNA, CTC testing, NGS platforms, and associated laboratory services.

Kuwait Liquid Biopsy Market

Kuwait’s liquid biopsy market is expanding as healthcare providers place greater emphasis on cancer prevention, molecular diagnostics, and personalized treatment. Breast cancer and other major oncology indications are creating demand for technologies that can complement conventional imaging and tissue-based diagnostics. Liquid biopsy provides a minimally invasive alternative or complementary approach by analyzing tumor-derived biomarkers from blood, allowing physicians to obtain molecular information without repeatedly collecting tumor tissue. Kuwait is also benefiting from regional investments in genomic medicine. In 2024, M42 and AstraZeneca announced a clinical genomics initiative spanning Kuwait, alongside the UAE, Oman, Bahrain, and Qatar, with a focus on hereditary breast-cancer gene sequencing and personalized prevention strategies. The program also included a companion-diagnostics component designed to support next-generation precision medicine. As Kuwait expands molecular laboratory capacity, liquid biopsy can support actionable mutation identification, therapy selection, treatment monitoring, and recurrence assessment. Growing awareness of early diagnosis and increasing availability of advanced genomic testing are expected to strengthen adoption across major hospitals and specialized oncology centers. The market should also benefit from GCC-wide collaboration, technology transfers, and the increasing availability of imported molecular diagnostic kits and reagents.

GCC Liquid Biopsy Market Segments:

Product

• Kits & Reagents
• Platforms & Instruments
• Services

Application

• Cancer Therapeutic Application
• Reproductive Health
• Other Therapeutic

Circulating Biomakers

• Circulating Tumor Cell
• Circulating Tumor DNA
• Cell-free DNA (cfDNA)
• Extracellular Vesicles
• Other Biomarkers

End User

• Hospitals
• Diagnostic Laboratories
• Point-of-care Testing
• Academic Institutes
• Others

Countries

• Saudi Arabia
• UAE
• Kuwait
• Qatar
• Oman
• Bahrain
• Rest of GCC

All companies have been covered with 5 Viewpoints

• Overviews
• Key Person
• Recent Developments
• SWOT Analysis
• Revenue Analysis

Key Players Analysis

• F. Hoffmann-La Roche Ltd.
• Bio-Rad Laboratories
• Thermo Fisher Scientific Inc.
• Johnson & Johnson
• Guardant Health Inc
• Guardant Health
• QIAGEN N.V
• Sysmex

Report Details: